Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | CLK3 | P49761 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.42 |
| ▸ | IL2 | P60568 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 5/20 | 0.35 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.35 |
| ▸ | CDK2 | P24941 | 3/20 | 0.35 |
| ▸ | IKBKB | O14920 | 2/20 | 0.35 |
| ▸ | CHUK | O15111 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | INSR | P06213 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | SGK1 | O00141 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25157935 | 1.00 | DYRK1A (0.44) | DYRK1ACLK2CLK3MAP4K1IL2 | |
| SCHEMBL25157103 | 0.91 | MAP3K11 (0.42) | DYRK1ACLK2CLK3MAP4K1IL2 | |
| SCHEMBL30347825 | 0.88 | DYRK1A (0.43) | DYRK1ACLK2CLK3MAP4K1IL2 | |
| SCHEMBL25518653 | 0.88 | DYRK1A (0.43) | DYRK1ACLK2CLK3MAP4K1IL2 | |
| SCHEMBL30346666 | 0.87 | DYRK1A (0.48) | DYRK1ACLK2CLK3MAP4K1IL2 | |
| SCHEMBL25196886 | 0.87 | DYRK1A (0.48) | DYRK1ACLK2CLK3MAP4K1IL2 | |
| SCHEMBL30347427 | 0.84 | DYRK1A (0.42) | DYRK1ACLK2CLK3MAP4K1IL2 | |
| SCHEMBL25518706 | 0.83 | TDO2 (0.42) | DYRK1ACLK2CLK3MAP4K1IL2 | |
| SCHEMBL30347565 | 0.83 | TDO2 (0.42) | DYRK1ACLK2CLK3MAP4K1IL2 | |
| SCHEMBL25158825 | 0.83 | DYRK1A (0.41) | DYRK1ACLK2CLK3MAP4K1IL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-04-24 | — | — | US | claimed |
| EP-4415818-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | claimed |
| WO-2023064361-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-4415818-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023064361-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | DYRK1A 1/4885CLK2 466/4885CLK3 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.